Insider Transactions in Q1 2022 at Rhythm Pharmaceuticals, Inc. (RYTM)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
William T. Roberts Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,023
-40.92%
|
$11,253
$11.13 P/Share
|
|
Mar 29
2022
|
William T. Roberts Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
-
|
|
Feb 15
2022
|
Jennifer Chien EVP, Head of North America |
SELL
Open market or private sale
|
Direct |
722
-35.53%
|
$4,332
$6.1 P/Share
|
|
Feb 15
2022
|
Yann Mazabraud EVP, Head of International |
SELL
Open market or private sale
|
Direct |
934
-45.96%
|
$5,604
$6.1 P/Share
|
|
Feb 15
2022
|
Hunter C Smith Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
833
-2.03%
|
$4,998
$6.1 P/Share
|
|
Feb 15
2022
|
Joseph Shulman Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
557
-35.64%
|
$3,342
$6.1 P/Share
|
|
Feb 11
2022
|
Jennifer Chien EVP, Head of North America |
BUY
Exercise of conversion of derivative security
|
Direct |
2,032
+50.0%
|
-
|
|
Feb 11
2022
|
Yann Mazabraud EVP, Head of International |
BUY
Exercise of conversion of derivative security
|
Direct |
2,032
+50.0%
|
-
|
|
Feb 11
2022
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,344
+5.41%
|
-
|
|
Feb 11
2022
|
Joseph Shulman Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,563
+50.0%
|
-
|